Synta Announces Advancement Of Ganetespib Into Phase 3 Extension Of AML LI-1 Study For Patients With AML And High-Risk MDS
July 21, 2014 at 16:30 PM EDT
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced the advancement of ganetespib into the Phase 3 extension of the AML LI-1 ...